NCT03522584View on ClinicalTrials.gov

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 17, 2018

Primary Completion Date

December 16, 2021

Study Completion Date

January 19, 2022

Conditions
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
Interventions
BIOLOGICAL

Durvalumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

BIOLOGICAL

Tremelimumab

Given IV

PROCEDURE

Hypofractionated Image-Guided Radiation Therapy

Undergo HIGRT

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

AstraZeneca

INDUSTRY

lead

University of Washington

OTHER